Abnova produce y desarrolla mas de 19.000 proteínas recombinantes, mas de 12.000 anticuerpos MaxPab, mas de 16.000 anticuerpos monoclonales y mas de 20.000 anticuerpos policlonales dirigidos al genoma humano.
VHH-His tag NanoAb™ Targeting Human ACE2, clone K150
VHH-His tag NanoAb™ Targeting Human Adeno-associated virus VP1, clone K102
VHH-His tag NanoAb™ Targeting Human BLyS, clone 9057
VHH-His tag NanoAb™ Targeting Human CD22, clone 4062
VHH-His tag NanoAb™ Targeting Human CD276, clone O014
VHH-His tag NanoAb™ Targeting Human CD276, clone O014 (FITC)